Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [2] - The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to inhibit the activity of B cells involved in autoimmune diseases without depleting them [2] - Zenas aims to leverage its experienced leadership and disciplined product acquisition strategy to identify and develop candidates that provide superior clinical benefits for patients [2] Upcoming Events - Zenas will present at the Citi's 2025 Biopharma Back to School Conference on September 2, 2025, at 1:00 p.m. ET [3] - The company will also participate in the Cantor Global Healthcare Conference 2025 on September 3, 2025, at 8:35 a.m. ET [3] - Additionally, Zenas is scheduled to present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, at 7:45 a.m. ET [3]

Core Insights - Kraig Biocraft Laboratories, Inc. has established two new rearing centers in a leading silk-producing region in Asia, replacing its original Prodigy Textiles pilot facility as the main production center [1][4]. Production Achievements - Since the opening of the first rearing center in early 2024, the company has produced more recombinant spider silk than in all previous years combined, indicating a significant increase in production capacity [2]. - The new rearing centers combine advanced biotechnology with the region's sericulture expertise, favorable climate, and established infrastructure, optimizing the production environment [2]. Operational Developments - The company has begun transferring equipment from the original pilot facility to the new commercial production centers, with completion expected by the end of August [3]. - The new facilities will be operated by the company's wholly owned subsidiary, Prodigy Silk, while the Prodigy Textile brand will continue as a DBA of Kraig Labs [3]. Strategic Milestones - The establishment of the new rearing centers represents a major milestone for Kraig Labs, aligning with its expansion objectives for 2025 and enhancing its ability to commercialize spider silk [4]. - This development is the result of nearly a decade of planning, positioning the company to leverage the region's advantages and its scientific advancements [4].

Core Insights - EDAP TMS SA has announced a letter of intent for a EUR 36 million credit facility with the European Investment Bank (EIB) to support the growth of Focal One Robotic HIFU in the treatment of early-stage prostate cancer [1][2] - The financing will enhance the company's balance sheet and provide low-interest funding accessible in tranches as needed [2] - The credit facility is expected to close by the end of Calendar Year 2025, pending final legal documentation [1] Company Overview - EDAP TMS SA is a leader in robotic energy-based therapies, developing and distributing minimally invasive medical devices using ultrasound technology [3] - The company introduced Focal One as a leading prostate focal therapy, with potential applications beyond prostate cancer [3]

SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced unaudited financial results for the quarter ended June 30, 2025. “The strong momentum we built in 2024 and early 2025 continued in the second quarter,” said Ziyu Shen, ECARX Chairman and CEO. “Revenue was US$155.6 million, reflecting the impact of typical seasonal headwinds and the timing of certain contracts, while the disciplined execution of our lean o ...

Company Overview - Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [2] - The company is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan [2] - Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX) [2] Upcoming Events - Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in fireside chats at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025 [1][2] - Each session will be webcast live and available on demand following the events [2] Investor Relations - For more information regarding Telix, including share price, SEC filings, and investor presentations, the Telix Investor Relations website can be visited [3] - Contact information for investor relations includes Ms. Kyahn Williamson for global inquiries and Annie Kasparian for U.S. inquiries [4]

Core Insights - Baker Hughes has secured a long-term service agreement with bp for the Tangguh LNG plant in Papua Barat, Indonesia, lasting 90 months, which includes spare parts, repair services, and engineering support for critical turbomachinery [1][5] - This agreement builds on a partnership that dates back to 2009, highlighting Baker Hughes' ongoing role in supporting bp's energy projects [2] - The Tangguh LNG facility is crucial for Indonesia's energy strategy and the Asia-Pacific region's energy supply, with Baker Hughes' support ensuring the reliability of essential turbomachinery [3] Company and Industry Summary - The agreement emphasizes Baker Hughes' commitment to advancing energy development in Indonesia and its strategic focus on LNG equipment asset management services [4][5] - Baker Hughes is collaborating with local partner PT Imeco Inter Sarana to meet local content requirements, showcasing its dedication to local engagement [4] - The company aims to expand its service capabilities in the Asia-Pacific region to address growing energy demands and transition needs [5]

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score U.S. regulatory submission for cemdisiran monotherapy is planned for the first quarter of 2026, pending discussions with the FDA TARRYTOWN, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary and key secondary endpoi ...

Company Overview - Amaero Ltd. specializes in the research, development, manufacture, and sale of refractory metals and specialty alloy powders, serving the defense, space, and aviation industries [5] - The company provides end-to-end additive manufacturing solutions, including services, equipment, and technology, particularly for clients in the Aviation Defense and Space sectors and the Tool and Die industry [5] - Established in 2013 with support from Monash University, Amaero aims to commercialize opportunities in metal 3D printing identified by the Monash Centre for Additive Manufacturing [5] Market Upgrade - Amaero Ltd. has qualified to trade on the OTCQX® Best Market, upgrading from the OTCQB® Venture Market, which is a significant milestone for the company [1][3] - The upgrade enhances the accessibility of Amaero shares to U.S. institutional and retail investors, thereby increasing visibility among these investors [4][3] Financial Standards and Compliance - To qualify for the OTCQX Market, companies must meet high financial standards, adhere to best practice corporate governance, and comply with applicable securities laws [3] - The OTCQX Market is designed for established, investor-focused U.S. and international companies, indicating Amaero's commitment to maintaining high operational standards [3] Leadership Commentary - Hank J. Holland, Amaero's Chairman and CEO, expressed delight over the upgrade, highlighting the company's strong portfolio of proprietary technologies and a growing pipeline of strategic partnerships [4] - The company is positioned to capitalize on the increasing adoption of additive manufacturing globally, indicating a positive outlook for future growth [4]

LOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two investor events in September. Event: H.C. Wainwright 27th Annual Global Investment Conference Type: Fireside chatDate/Time: Wednesday, September 10, 2025, at 8:30 a.m. ET Event: Truist Securities Vir ...

EATONTOWN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB), is excited to announce a strategic partnership with Coro. This partnership aims to leverage the strengths of both companies to deliver comprehensive cybersecurity solutions to a broader market. As cyber threats continue to evolve and SMBs and distributed enterprise face increasing security and compliance pres ...